The expression levels of pyrimidine metabolic rate–limiting enzymes CAD, CTPS, DTYMK, RRM1, RRM2, TYMS, UCK2, and TK1 were particularly higher in TP53 mutant lung cancer patients (Fig. 8c). This evidence concerns the gene RRM1 and lung carcinoma.